ライフサイエンスコーパス: progression of disease

1 se, whereas all patients with IPF experience progression of disease.

2 ions in both conditions but do not alter the progression of disease.

3 in which cytokines play a major role in the progression of disease.

4 eled deterioration of motor performance with progression of disease.

5 specific CD8(+) T cells were associated with progression of disease.

6 ly type 1 diabetic (T1D) patients during the progression of disease.

7 oncogene thought to be an early event in the progression of disease.

8 16 stable disease, 15 mixed response, and 36 progression of disease.

9 tic wall inflammation that may portend rapid progression of disease.

10 oint which mutations influence the onset and progression of disease.

11 ter surgery, 11.1% experienced recurrence or progression of disease.

12 s that break down during the development and progression of disease.

13 decrease in satellite cells correlated with progression of disease.

14 ides is critical for both the initiation and progression of disease.

15 macrophage content in plaque, and attenuated progression of disease.

16 ty, which is associated with development and progression of disease.

17 s extremely effective in reducing flares and progression of disease.

18 ADAM12 protein levels in urine increase with progression of disease.

19 ns for development of new therapies to block progression of disease.

20 action between macrophages and CX3CL1 in the progression of disease.

21 physiological control and for the onset and progression of disease.

22 ication may functionally regulate metastatic progression of disease.

23 conditions and environmental factors in the progression of disease.

24 dence for the involvement of steroids in the progression of disease.

25 ms seem to be important for the onset and/or progression of disease.

26 ence of guttae and has been used to document progression of disease.

27 resented to examine failure phenomena in the progression of disease.

28 tegrity is detrimental and implicated in the progression of disease.

29 mg daily and to consider dose escalation on progression of disease.

30 se development may prevent diabetes or delay progression of disease.

31 out of the perivascular space and leading to progression of disease.

32 nses, leading to the control of infection or progression of disease.

33 ses of HD and is associated with subclinical progression of disease.

34 ds the ability to monitor both the onset and progression of disease.

35 can potentially affect various steps in the progression of disease.

36 tly implicate tau abnormalities in the onset/progression of disease.

37 n many cancers and can drive the genesis and progression of disease.

38 ed continuously beginning on day 1 and until progression of disease.

39 are implicated directly in the onset and/or progression of disease.

40 e system that facilitate the development and progression of disease.

41 et in individual mice, we were able to track progression of disease.

42 , a highly angiogenic cytokine that supports progression of disease.

43 with an unusual joint distribution and rapid progression of disease.

44 ng cessation can reduce symptoms and prevent progression of disease.

45 atory agents) directed at slowing or halting progression of disease.

46 riety of organs and to observe the onset and progression of disease.

47 llowed by increased uptake of 18F-FDG during progression of disease.

48 The expression of endoglin increased with progression of disease.

49 ctivation of inflammation contributes to the progression of disease.

50 count and HIV RNA level as predictors of the progression of disease.

51 ops into severe ataxia or paralysis with the progression of disease.

52 ot appear to either accelerate or retard the progression of disease.

53 of DNA encoding the CR1 genes prevented the progression of disease.

54 peptide accelerated rather than retarded the progression of disease.

55 patient was when onset occurred and rate of progression of disease.

56 alive without evidence of local or systemic progression of disease.

57 ediate virus dissemination and contribute to progression of disease.

58 ls of HIV-1 RNA than those with slower or no progression of disease.

59 with a faster rate of CD4 T-cell decline and progression of disease.

60 te HIV-1 infection influences the subsequent progression of disease.

61 ith selegiline or alpha-tocopherol slows the progression of disease.

62 remained elevated in spinal cord throughout progression of disease.

63 utralizing virus in vitro increased with the progression of disease.

64 ed with hematopoietic malfunction during the progression of disease.

65 a223 to SABR MDT in BM omCSPC does not delay progression of disease.

66 s a role in the ongoing bile duct injury and progression of disease.

67 liver fibrosis, portal hypertension, and the progression of disease.

68 lect individuals at risk for AD and halt the progression of disease.

69 increased TFF expression to prevent further progression of disease.

70 ose of their respective subtypes, during the progression of disease.

71 initiated, perpetuated, and connected in the progression of disease.

72 are believed to play important roles in the progression of disease.

73 at is associated with change in the onset or progression of disease.

74 re protective while others contribute to the progression of disease.

75 to understand their role in the development/progression of disease.

76 nt and maintenance of the glomerulus and the progression of disease.

77 able to undergo surgery as a result of local progression of disease.

78 mis and how these adaptations can define the progression of disease.

79 pathways, contributes to the initiation and progression of disease.

80 k factors is important to help limit further progression of disease.

81 n of new functions and in the appearance and progression of disease.

82 tions in both HFpEF and cancer contribute to progression of disease.

83 xtracellular protein aggregates in mediating progression of disease.

84 ts of Mendelian and somatic mutations on the progression of disease.

85 mitochondrial dysfunction and development or progression of disease.

86 mediators at specific points in time in the progression of disease.

87 cooperating mutations that are necessary for progression of disease.

88 up differences were observed in radiographic progression of disease.

89 uals, enable early diagnosis and reflect the progression of disease.

90 or disease classification and to monitor the progression of diseases.

91 er of illness, or can intervention alter the progression of disease?

92 dacarbazine group (hazard ratio for death or progression of disease, 0.43; 95% CI, 0.34 to 0.56; P<0.

93 itions of cure as it applies to MS: (1) halt progression of disease, (2) reverse neurological deficit

94 ange, 8 to 45+ months), 5 patients (42%) had progression of disease 8, 12, 18, 23, and 39 months from

95 used mixed modelling techniques to model the progression of disease according to these predictors, al

96 of type of resistance (primary vs secondary, progression of disease [acute leukemia or higher risk MD

97 bacteria in the intestinal flora and relapse/progression of disease after allo-HCT.

98 sed Hodgkin's lymphoma, 44 (90%) of whom had progression of disease after previous autologous transpl

99 ding patients with newly diagnosed cancer or progression of disease after remission.

100 e) OAC or other treatment methods because of progression of disease after second-line OAC, particular

101 In patients with stage III disease without progression of disease after therapy, PCI decreased the

102 Progression of disease also was correlated with increase

103 tion model in which we observed a more rapid progression of disease and a greater recovery rate for t

104 of endometrial cancer associated with rapid progression of disease and a poor prognosis.

105 sing questions about the determinants of the progression of disease and age at onset.

106 Progression of disease and bypass graft attrition result

107 re surveillance is encouraged to monitor for progression of disease and complications of gastroesopha

108 n and median time from the last treatment to progression of disease and death (if applicable) was als

109 The relative risks of progression of disease and death among the 183 women ass

110 bition as a therapeutic strategy to slow the progression of disease and delay cancer recurrence in in

111 rated greater deficits across the brain with progression of disease and development of dementia, part

112 ion of treatment was associated with greater progression of disease and did not confer immunologic or

113 n KO mice with wild-type spleen cells halted progression of disease and favored recovery.

114 reatment after disease onset potently blocks progression of disease and further alpha-motoneuron dege

115 processes may be beneficial for halting the progression of disease and improving quality of life in

116 ing and treatment of CMV retinitis may limit progression of disease and may prevent visual impairment

117 Treatment is needed to prevent progression of disease and minimize recurrence after liv

118 SC-EPOCH-RR group, the rates of freedom from progression of disease and overall survival were, respec

119 Several nutritional factors modify the progression of disease and prognosis after the diagnosis

120 aphy may be helpful in diagnosis, monitoring progression of disease and response to treatment.

121 er, approximately 20% of patients have early progression of disease and short OS.

122 ion; the test may be useful to follow up the progression of disease and the effect of treatment.

123 y weight, given every two weeks; the time to progression of disease and the response rate were primar

124 the oral cavity, and this may influence the progression of diseases and/or aging changes at this sit

125 had stable IFD at the end of therapy without progression of disease, and 6 (16%) patients had progres

126 nt role in drug metabolism, in the onset and progression of disease, and can be harnessed for prodrug

127 Medical treatment does not slow the progression of disease, and many patients need liver tra

128 as in therapies to ameliorate symptoms, slow progression of disease, and mitigate the risk of adverse

129 easures were control of ocular inflammation, progression of disease, and surgical success.

130 e primary determinant of clinically apparent progression of disease, and that future experimental the

131 events such as plaque rupture, to follow the progression of disease, and to select appropriate therap

132 With progression of disease, approximately 50% of mice acquir

133 t revascularization due to restenosis and/or progression of disease are largely unknown.

134 pathogenic mechanisms driving the onset and progression of disease are not clearly defined.

135 Nevertheless, overall onset and progression of disease are unaffected in C1q- and C3-del

136 e the first scan, and one patient (3.1%) had progression of disease as best response.

137 ent followed by 2 weeks off treatment, until progression of disease as determined by the investigator

138 The model recapitulated the progression of disease as seen during experimental infec

139 ears, namely prevention of exacerbations and progression of disease, as well as primary intervention,

140 ular interactions important in the onset and progression of disease, assessing the biologic relevance

141 ficant implications for the pathogenesis and progression of diseases associated with amyloid depositi

142 s to our understanding of the initiation and progression of diseases associated with dysregulated met

143 these genes is linked to the initiation and progression of diseases associated with exacerbated infl

144 striatal dopamine neurons, as well as in the progression of diseases associated with this system, e.g

145 Recently, time to progression of disease at 24 months (POD24) was identifi

146 homa (MZL) who experience early progression (progression of disease at 24 months [POD24]) have poor s

147 Both improved survival and less progression of disease at 5 years after elective TEVAR w

148 dentifiable, high prevalence group, allowing progression of disease at a time when therapeutic advanc

149 res that accurately reflect the pathological progression of disease at each stage.

150 Three patients showed progression of disease at the treated levels at follow-u

151 fibre density, age-at-onset of symptoms and progression of disease burden, as measured by the Newcas

152 nts who did not undergo surgery did not have progression of disease, but approximately one quarter of

153 A total of 11/16 patients showed progression of disease by EM on follow-up biopsy.

154 rom both patients and animal models that the progression of disease can vary greatly and can be modif

155 The potential for rapid progression of disease caused by encapsulated bacteria p

156 it required for filament assembly, onset and progression of disease caused by familial ALS-linked SOD

157 of various human diseases, including delayed progression of disease caused by human immunodeficiency

158 Some animals experienced rapid progression of disease characterized by loss of greater

159 Spatio-temporal progression of disease could be described as the sum of

160 er, 14 of these 52 patients (27 percent) had progression of disease, defined as the development of at

161 cellular pathology and continuing throughout progression of disease demonstrates that tyrosine nitrat

162 Even when tumors are initially responsive, progression of disease despite continued taxane therapy

163 both processes contribute to persistence and progression of disease, despite anti-inflammatory therap

164 therapeutic regimens which prevent or delay progression of disease due to resistance.

165 ies or groups of related species and relapse/progression of disease during 2 years of follow-up time

166 sistance to paclitaxel was defined as either progression of disease during treatment, failure to achi

167 stand the role of protein aggregation in the progression of disease etiology, we performed a screen f

168 ontrol, drug resistance followed by clinical progression of disease eventually occurs in virtually al

169 Clinical progression of disease following initiation of HAART was

170 ocytes can contribute to the development and progression of diseases for which acute or chronic infla

171 Infants with a rapid progression of disease had higher peak HIV-1 RNA levels

172 The fulminant progression of disease has been largely ascribed to the

173 mediated inflammation in the acceleration or progression of disease has been proposed.

174 of miRNA, their involvement in the onset and progression of disease has generated significant interes

175 associated with a decreased risk of relapse/progression of disease (hazard ratio [HR], 0.82 per 10-f

176 edictable onset, ease of transmission, rapid progression of disease, high mortality and lack of effec

177 udy were 5.7 times more likely to experience progression of disease (HR = 5.70; 95% confidence interv

178 esence also was associated with less relapse/progression of disease (HR, 0.52; 95% CI, 0.31 to 0.87;

179 ns and did not exacerbate EAE, but i) halted progression of disease, ii) reversed neurological defici

180 dulates aggregation and delays the onset and progression of disease in a full-length model of HD, BAC

181 production of collagen-specific Abs and the progression of disease in a mouse model of rheumatoid ar

182 that when administered topically curbed the progression of disease in a novel rabbit model of mild P

183 emented cases and remained higher throughout progression of disease in all regions examined.

184 ue injury in a developing fetus and clinical progression of disease in an asymptomatic mother found t

185 aseI gene has been shown to be important for progression of disease in both the murine and human form

186 ested the effect of CTLA4Ig treatment on the progression of disease in BXSB males.

187 The development and progression of disease in childhood is likely to carry i

188 f injury and inflammation increased with the progression of disease in coal miners.

189 odel for investigating NTHi pathogenesis and progression of disease in COPD.

190 f endothelial dysfunction does contribute to progression of disease in early heart failure, specific

191 However, progression of disease in female Cy/+ rats, assessed in

192 Large SDs reflected variable progression of disease in individual patients on standar

193 amin A palmitate and omega-3-rich fish, slow progression of disease in many patients.

194 This is in contrast to the rapid progression of disease in mice lacking IFN-gamma or a ke

195 l number and behavior that may relate to the progression of disease in myotubularin deficiency, and m

196 new-onset inflammation and the high risk of progression of disease in new-onset ulcerative proctitis

197 o diabetes onset can significantly delay the progression of disease in NOD mice.

198 lusively on memory CD4(+) T cells during the progression of disease in NOD mice.

199 To date, the anatomical progression of disease in non-amnestic patients remains

200 ence of disease in the transplanted organ or progression of disease in other organs.

201 duced survival in ovarian cancer and earlier progression of disease in ovarian and endometrial cancer

202 izumab can significantly prolong the time to progression of disease in patients with metastatic renal

203 based biomarkers to monitor the activity and progression of disease in patients with ulcerative colit

204 sponse in three, stable findings in one, and progression of disease in six.

205 xamined the effect of these compounds on the progression of disease in SMN lacking exon 7 (SMNDelta7)

206 oligotyping may be useful in predicting the progression of disease in some Caucasian patients.

207 early development of symptoms and the rapid progression of disease in some vertically infected infan

208 as a significant prolongation of the time to progression of disease in the high-dose--antibody group

209 y donor with HELLP syndrome and describe the progression of disease in the liver during cold storage.

210 borderline significance, between the time to progression of disease in the low-dose--antibody group a

211 splenic neutrophils at several stages in the progression of disease in the NZB/W murine model of lupu

212 oviding a molecular explanation for the slow progression of disease in these children.

213 based intervention strategies to prevent the progression of disease in utero are also discussed.

214 Similarly to progression of disease in women, ovarian neoplasms sprea

215 docosahexaenoic acid (DHA) can mitigate the progression of diseases in which oxidative stress repres

216 roach ideally involves strategies to prevent progression of disease, in addition to prediction of suc

217 ion with other insults trigger the onset and progression of disease, in both familial and idiopathic

218 ession, gene regulation, development and the progression of diseases including cancer.

219 Progression of disease is clearly evident in the positro

220 hat induce protective immunity or retard the progression of disease is important for AIDS vaccine dev

221 is chronic airflow impairment, but the early progression of disease is not well defined or understood

222 With current therapies such as epoprostenol, progression of disease is slowed, but not halted.

223 However, its role in the progression of disease is still being elucidated.

224 een visual emphysema patterns and subsequent progression of disease may provide a way to enrich a stu

225 mmon reasons for not undergoing surgery were progression of disease (n = 13) and patient choice (n =

226 these findings could help explain the rapid progression of disease observed in some HIV-1-infected c

227 Relapse or progression of disease occurred in 54 children.

228 n nine patients (15%), and three deaths from progression of disease occurred within 30 days of withdr

229 Progression of diseases of the exocrine pancreas, which

230 Two patients with progression of disease on standard three-week paclitaxel

231 muscular inoculation results in a more rapid progression of disease onset, whereas the incubation tim

232 avenously over 2 hours, every 21 days, until progression of disease or adverse effects prohibited fur

233 progression-free survival (hazard ratio for progression of disease or death from any cause, 1.05; 95

234 The relative risk of progression of disease or death was 0.57 (95% CI, 0.43 t

235 The relative risks of progression of disease or death were 0.57 (95 percent co

236 Study endpoints were clinical evidence of progression of disease or death.

237 with AZD4547, 80 mg orally twice daily until progression of disease or drug intolerance.

238 those with stable disease were treated until progression of disease or intolerable toxicity.

239 risk of significant disease at diagnosis and progression of disease over time.

240 tor pathways leads to the development and/or progression of disease, particularly in the context of c

241 One example of this is the progression of disease pathology found in both the neoco

242 ble disease (SD) and seven (23%) experienced progression of disease (PD).

243 + bevacizumab or observation until the first progression of disease (PD1); and p2, during capecitabin

244 oduction treatment from PD1 until the second progression of disease (PD2).

245 ncy that enabled us to control the onset and progression of disease phenotypes by the modulation of F

246 has important limitations when assessing for progression of disease (POD) versus treatment-related ch

247 nts with follicular lymphoma (FL) experience progression of disease (POD) within 2 years of initial c

248 However, the histological progression of disease, predictors of recurrence and dis

249 nhibitor), a papular eruption concerning for progression of disease prompted cessation of treatment.

250 matrix-adhesion pathways are involved in the progression of disease regardless of the primary insult.

251 Dysphagia may occur during the progression of disease regardless of whether the patient

252 l insults and prevent disease or inhibit the progression of diseases related to oxidative stress.

253 UDCA therapy had no effect on delaying progression of disease (relative risk, 0.95; 95% confide

254 We investigated the appearance and progression of disease-relevant signs in the B6.Htt(Q111

255 ectiveness and safety of RFA, recurrence and progression of disease remain an issue in a subset of pa

256 therapies to limit vascular leak during the progression of disease requires a more complete understa

257 d subsequent clinical events: restenosis and progression of disease requiring coronary artery bypass

258 it from treatment with an EGFR TKI; systemic progression of disease (Response Evaluation Criteria in

259 Symptoms also increase with progression of disease severity.

260 sible by our enhanced ability to monitor the progression of disease, should make it possible to study

261 ting time and, as a result, may decrease the progression of disease so that intuitively the recurrenc

262 address both the cognitive and the biologic progression of disease state in individual subjects.

263 ase activity has long been recognized in the progression of disease states such as cancer and inflamm

264 to growth retardation in several organs and progression of disease states such as transient neonatal

265 Abnormal LPA expression can lead to the progression of diseases such as cancer and fibrosis.

266 oles in tissue remodelling and repair and in progression of diseases such as cancer, arthritis, ather

267 drive disorganization of tissues and promote progression of diseases such as cancer.

268 ursors (dicarbonyls) are associated with the progression of diseases such as diabetes and cardiovascu

269 ed extracellular matrix (ECM) which promotes progression of diseases such as hepatocellular carcinoma

270 pregnancy outcomes, as well as its effect on progression of diseases such as HIV infection.

271 ry responses may lead to the development and progression of diseases such as hypertrophic cardiomyopa

272 ian E- and N-cadherins might function in the progression of diseases such as metastatic ovarian cance

273 lene evolution occurs concomitantly with the progression of disease symptoms in response to many viru

274 ated with a significantly longer time to the progression of disease than was treatment with cisplatin

275 A-B57 are associated with protection against progression of disease that results from infection with

276 might participate in the development and/or progression of diseases that include repeat-associated c

277 n potentially help clinicians to predict the progression of diseases, there is no method so far that

278 onally effective in slowing or reversing the progression of disease though a significant number of pa

279 s a long-lasting protection and prevents the progression of disease to severe manifestations.

280 y understood and often results in sufficient progression of disease to warrant evaluation for lung tr

281 lue, and elevated LDH increased the risk for progression of disease under PSMA RLT.

282 nal failure (ischemic nephropathy) caused by progression of disease, usually atherosclerotic in natur

283 tment began within 2 weeks of birth, and the progression of disease was followed over time using beha

284 atal bronchopneumonia in X-CGD mice, whereas progression of disease was slower at lower doses, with d

285 xtranuclear mutant htt on the initiation and progression of disease, we generated a series of transge

286 IL-17 significantly reduces the severity and progression of disease, which is paralleled by a reducti

287 tential biomarkers that are sensitive to the progression of disease, which might enhance the diagnost

288 hs of life are at increased risk for a rapid progression of disease, which suggests that early treatm

289 intestinal homeostasis and in the onset and progression of disease with a major focus on understandi

290 y, providing new insight into the origin and progression of disease with increasing age.

291 model of melioidosis and to characterize the progression of disease with respect to clinical presenta

292 animals showed a significant slowing of the progression of disease with weight loss attenuation, enh

293 ent of the inflammasome in the initiation or progression of diseases with a high impact on public hea

294 cycline therapy, 12 of whom had demonstrated progression of disease within 12 months of it.

295 Posttreatment surrogate end points, such as progression of disease within 24 months (POD24) are prom

296 (FL) and high-risk disease features, such as progression of disease within 24 months (POD24) from fir

297 Progression of disease within 24 months (POD24) occurred

298 with follicular lymphoma (FL) who experience progression of disease within 24 months (POD24) remains

299 Concerning progression of disease within 24-months (POD-24), clinic

300 nd used intravital microscopy to monitor the progression of disease within the bone marrow at both th